Merck, Inc.

🇵🇭Philippines
Ownership
Subsidiary
Employees
-
Market Cap
$295.3B
Website
http://www.merck.ph
Clinical Trials
Related News

An Eighteen Month Efficacy and Safety Study in Obese Patients (0364-020)(COMPLETED)

First Posted Date
2005-08-18
Last Posted Date
2016-06-07
Lead Sponsor
Merck Sharp & Dohme LLC
Target Recruit Count
500
Registration Number
NCT00131430

Concomitant Use and Staggered Use of Vaccine and Oral Poliovirus (OPV) in Healthy Infants (V260-014)(COMPLETED)

First Posted Date
2005-08-16
Last Posted Date
2015-04-01
Lead Sponsor
Merck Sharp & Dohme LLC
Target Recruit Count
735
Registration Number
NCT00130832

A Study to Evaluate Safety, Tolerability, and Immunogenicity of an Investigational Zoster Vaccine In Subjects With a History of Varicella (Chickenpox)(V211-010)(COMPLETED)

Phase 3
Completed
Conditions
Herpes Zoster
First Posted Date
2005-08-16
Last Posted Date
2015-01-26
Lead Sponsor
Merck Sharp & Dohme LLC
Target Recruit Count
368
Registration Number
NCT00130793

An Investigational Drug Co-Administered With Insulin in Patients With Type 2 Diabetes (0478-065)

Phase 3
Terminated
Conditions
Type 2 Diabetes Mellitus
First Posted Date
2005-08-16
Last Posted Date
2016-09-07
Lead Sponsor
Merck Sharp & Dohme LLC
Target Recruit Count
600
Registration Number
NCT00130806

A Study in Pediatric Patients With Cystic Fibrosis Lung Disease

Phase 2
Completed
Conditions
Cystic Fibrosis
First Posted Date
2005-08-15
Last Posted Date
2013-05-22
Lead Sponsor
Merck Sharp & Dohme LLC
Target Recruit Count
13
Registration Number
NCT00130182
Locations
🇺🇸

General Clinic Research Center University of Minnesota, Minneapolis, Minnesota, United States

🇺🇸

The Minnesota CF Center, Minneapolis, Minnesota, United States

🇺🇸

The Children's Hospital, Denver, Colorado, United States

Suberoylanilide Hydroxamic Acid (Vorinostat, MK-0683) Versus Placebo in Advanced Malignant Pleural Mesothelioma (MK-0683-014)

Phase 3
Completed
Conditions
Mesothelioma
Lung Cancer
Interventions
Drug: Placebo
Drug: Vorinostat
First Posted Date
2005-08-09
Last Posted Date
2020-10-26
Lead Sponsor
Merck Sharp & Dohme LLC
Target Recruit Count
661
Registration Number
NCT00128102

Treatment of Sarcopenia in Post-Hip Fracture Patients (0677-032)

Phase 2
Terminated
Conditions
Hip Fracture
First Posted Date
2005-08-09
Last Posted Date
2016-01-20
Lead Sponsor
Merck Sharp & Dohme LLC
Target Recruit Count
83
Registration Number
NCT00128115
Locations
🇳🇴

MSD (Norge) AS, Drammen, Norway

🇸🇪

Merck Sharp & Dohme (Sweden) AB, Sollentuna, Sweden

🇩🇪

Msd Sharp & Dohme Gmbh, Haar, Germany

and more 2 locations

An Investigational Study of a Histone Deacetylase (HDAC) Inhibitor Plus Targretin in Cutaneous T-Cell Lymphoma Patients (0683-016)(TERMINATED)

Phase 1
Terminated
Conditions
Lymphoma
Interventions
Drug: vorinostat
First Posted Date
2005-08-05
Last Posted Date
2015-04-21
Lead Sponsor
Merck Sharp & Dohme LLC
Target Recruit Count
23
Registration Number
NCT00127101

A Study of Vorinostat in Patients With Solid Tumors (MK-0683-029)

Phase 1
Completed
Conditions
Tumors
Interventions
Drug: vorinostat
First Posted Date
2005-08-05
Last Posted Date
2022-09-13
Lead Sponsor
Merck Sharp & Dohme LLC
Target Recruit Count
18
Registration Number
NCT00127127

A Study of an Investigational Drug Sitagliptin for Type 2 Diabetes Mellitus (0431-044)

Phase 2
Completed
Conditions
Type 2 Diabetes Mellitus
Interventions
Drug: sitagliptin phosphate
First Posted Date
2005-08-05
Last Posted Date
2015-06-15
Lead Sponsor
Merck Sharp & Dohme LLC
Target Recruit Count
363
Registration Number
NCT00127192
© Copyright 2024. All Rights Reserved by MedPath
HomeTerms & ConditionsPrivacy Policy